Growth in the Medical Field
First written in FY2017-Q1. 17 of 43 entries say "Advanced", first in FY2020-Q1. Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1AdvancedAnnual report
「In the interim consolidated period, the medical business generated revenue of ¥3,976 million (110.9% year on year) and segment profit (operating profit) of ¥1,585 million (127.1% year on year), as the number of physician-placement contracts exceeded the prior-year period and progressed steadily.」
The number of successful physician placements exceeded the previous year’s level, resulting in higher revenue and profit in the Medical segment. - 2026-10-08Advancedgamebiz.jp
「医師紹介の成約数が前年同期を上回って順調に推移した結果、売上高39億7600万円（同10.9％増）、セグメント利益（営業利益）15億8500万円（同27.1％増）となった。」
医療分野は第2四半期累計で売上高とセグメント利益が前年同期を上回り、成長実績が具体化した。 - FY2026AdvancedAnnual report
「Performance in the medical field during the current consolidated fiscal year benefited from the number of successful physician placements exceeding the prior-year period and progressing steadily. Revenue was ¥5,782 million (108.9% of the previous fiscal year), and segment profit (operating profit) was ¥1,437 million (132.7% of the previous fiscal year).」
The number of successful physician placements exceeded the prior-year period, and both revenue and segment profit increased in the medical field. - FY2026-H1AdvancedAnnual report
「Performance in the medical field benefited from the number of successful physician placements exceeding the prior-year period and progressing steadily. Revenue was ¥3,584 million (109.7% of the prior-year period), and segment profit (operating profit) was ¥1,247 million (122.4% of the prior-year period).」
From the revenue and profit declines in the interim period of the previous fiscal year, the number of successful physician placements exceeded the prior-year period, and the current interim period moved into revenue and profit growth. - FY2025-H1WorsenedAnnual report
「During the current interim consolidated accounting period, performance in the medical field was affected by a decline in the number of successful placements due to delays in the effects of the sales-structure review implemented since the second half of the previous fiscal year. Revenue was ¥3,267 million (97.6% of the prior-year period), and segment profit (operating profit) was ¥1,019 million (86.7% of the prior-year period).」
The effects of the sales-structure review were delayed, and the decline in successful placements resulted in lower revenue and profit in the medical field. - FY2025-Q1WorsenedAnnual report
「During the first quarter of the current consolidated fiscal year, performance in the medical field was affected by structural reforms, including the review of the sales structure implemented since the second half of the previous fiscal year. Revenue was ¥1,747 million (95.4% of the prior-year period), and segment profit (operating profit) was ¥708 million (90.0% of the prior-year period).」
The impact of structural reforms, including the review of the sales structure, resulted in year-on-year declines in both revenue and profit in the medical field. - FY2024Higher revenue, lower profitAnnual report
「As a result, revenue in the medical field was ¥5,417 million (103.6% of the prior-year period), and segment profit (operating profit) was ¥1,293 million (96.6% of the prior-year period).」
Revenue in the medical field exceeded the prior-year period, while segment profit fell below the prior-year period due mainly to a decline in spot vaccine-inoculation projects. - FY2024-Q3Higher revenue, lower profitAnnual report
「As a result, revenue in the medical field was ¥4,460 million (104.1% of the prior-year period), and segment profit (operating profit) was ¥1,278 million (98.7% of the prior-year period).」
Revenue in the medical field increased year on year, while segment profit fell below the prior-year period due mainly to a decline in spot vaccine-inoculation projects. - FY2024-Q2AdvancedAnnual report
「As a result, revenue in the medical field was ¥3,347 million (105.1% of the prior-year period), and segment profit (operating profit) was ¥1,175 million (102.5% of the prior-year period).」
From the revenue growth and profit decline in FY2024-Q1, both revenue and segment profit exceeded the prior-year period on a cumulative FY2024-Q2 basis, moving into revenue and profit growth. - FY2024-Q1WorsenedAnnual report
「As a result, revenue in the medical field was ¥1,832 million (101.3% of the prior-year period), and segment profit (operating profit) was ¥787 million (93.6% of the prior-year period).」
Revenue in the medical field increased year on year, while segment profit fell below the prior-year period due to a decline in spot vaccine-inoculation projects. - FY2023AdvancedAnnual report
「As a result, revenue in the medical field was ¥5,226 million (118.6% of the prior-year period), and segment profit (operating profit) was ¥1,339 million (154.1% of the prior-year period).」
Revenue in the medical field was ¥5,226 million and segment profit was ¥1,339 million, marking further progress in both revenue and profit growth. - FY2023-Q3AdvancedAnnual report
「As a result, the medical segment recorded revenue of ¥4,282 million, up 118.6% year on year, and segment profit (operating profit) of ¥1,295 million, up 138.1%.」
In the medical field, revenue was 118.6% of the prior-year period and segment profit was 138.1%, marking further progress in both revenue and profit growth. - FY2023-Q2AdvancedAnnual report
「As a result, the medical segment recorded revenue of ¥3,185 million, up 121.6% year on year, and segment profit (operating profit) of ¥1,146 million, up 138.8%.」
Medical segment revenue was 121.6% of the previous year’s corresponding period and segment profit was 138.8%, indicating further growth in revenue and profit. - FY2023-Q1AdvancedAnnual report
「As a result, the medical segment recorded revenue of ¥1,809 million, up 122.8% year on year, and segment profit (operating profit) of ¥840 million, up 151.1%.」
Medical segment revenue and segment profit increased from ¥1,473 million and ¥556 million, respectively, in the previous year’s corresponding period, to ¥1,809 million and ¥840 million. - FY2022AdvancedAnnual report
「As a result, the medical segment recorded revenue of ¥4,406 million, up 112.3% year on year, and segment profit (operating profit) of ¥869 million, up 120.1%.」
Medical segment revenue and segment profit increased from ¥3,923 million and ¥723 million, respectively, in the previous fiscal year. - FY2022-Q3AdvancedAnnual report
「As a result, the medical segment recorded revenue of ¥3,610 million, up 115.5% year on year, and segment profit (operating profit) of ¥937 million, up 127.3%.」
Medical segment revenue was 115.5% of the previous year’s corresponding period and segment profit was 127.3%, continuing the increase in revenue and profit from the previous cumulative second quarter. - FY2022-Q2AdvancedAnnual report
「As a result, the medical segment recorded revenue of ¥2,618 million, up 113.7% year on year, and segment profit (operating profit) of ¥826 million, up 124.0%.」
The medical segment continues to post year-on-year increases in both revenue and segment profit, with higher revenue and profit. - FY2022-Q1Reversal to higher revenue and profitAnnual report
「As a result, the medical segment recorded revenue of ¥1,473 million, up 112.3% year on year, and segment profit (operating profit) of ¥556 million, up 117.2%.」
The quarter turned from lower revenue and profit due to the impact of COVID-19 in the previous fiscal year to higher revenue and profit, with both revenue and segment profit exceeding the previous year’s corresponding period. - FY2021WorsenedAnnual report
「As a result, the medical segment recorded revenue of ¥3,923 million, down to 96.5% of the previous year’s corresponding period, and segment profit (operating profit) of ¥723 million, down to 97.8%.」
The medical segment posted lower full-year revenue and profit due to the impact of Reginavi Fair cancellations and other factors. - FY2021-Q3WorsenedAnnual report
「As a result, the medical segment recorded revenue of ¥3,125 million, down to 92.7% of the previous year’s corresponding period, and segment profit (operating profit) of ¥736 million, down to 90.9%.」
The medical segment posted lower revenue and profit year on year as the impact of Reginavi Fair cancellations continued. - FY2021-Q2WorsenedAnnual report
「As a result, the medical segment recorded revenue of ¥2,302 million, down to 90.0% of the previous year’s corresponding period, and segment profit (operating profit) of ¥666 million, down to 88.9%.」
Due to the impact of cancelling Reginavi Fair events because of COVID-19, the medical segment posted lower revenue and profit year on year, deteriorating from the near-flat performance in Q1. - FY2021-Q1Revenue and profit flat amid COVID-19Annual report
「As a result, the medical segment recorded revenue of ¥1,312 million, down to 99.3% of the previous year’s corresponding period, and segment profit (operating profit) of ¥474 million, up 100.5%.」
Due in part to the impact of event cancellations caused by COVID-19, revenue fell below the previous year’s corresponding period, while segment profit was largely unchanged from the previous year’s corresponding period, reversing the previous trend of higher revenue and profit. - FY2020-Q3RestatedAnnual report
「As a result, the medical segment recorded revenue of ¥3,368 million, up 110.0% year on year, and segment profit (operating profit) of ¥810 million, up 135.0%.」
Maintains the trend of medical segment revenue and segment profit exceeding the previous year’s corresponding period, driven by the physician placement business. - FY2020-Q2RestatedAnnual report
「As a result, the medical segment recorded revenue of ¥2,556 million, up 109.8% year on year, and segment profit (operating profit) of ¥749 million, up 117.4%.」
Both medical segment revenue and segment profit exceeded the previous year’s corresponding period and progressed steadily, driven by the physician placement business. - FY2020-Q1AdvancedAnnual report
「Revenue and segment profit for the cumulative first quarter of the consolidated fiscal year exceeded the previous year’s corresponding quarter and progressed strongly. As a result, the medical segment recorded revenue of ¥1,321 million, up 111.7% year on year, and segment profit (operating profit) of ¥472 million, up 129.4%.」
Medical segment revenue was ¥1,321 million and segment profit was ¥472 million, with both revenue and profit increasing year on year. - FY2019Revenue Up, Profit DownAnnual report
「As a result, the medical segment recorded revenue of ¥3,708 million, up 104.2% from the previous fiscal year, and segment profit (operating profit) of ¥533 million, down to 92.7%.」
Full-year medical segment revenue exceeded the previous fiscal year, while segment profit fell below it. - FY2019-Q3RestatedAnnual report
「As a result, the medical segment recorded revenue of ¥3,063 million, up 104.6% year on year, and segment profit (operating profit) of ¥600 million, up 103.2%.」
States that both medical segment revenue and segment profit exceeded the previous year’s corresponding period and progressed broadly in line with plan. - FY2019-Q2RestatedAnnual report
「As a result, the medical segment recorded revenue of ¥2,327 million, up 100.9% year on year, and segment profit (operating profit) of ¥638 million, down to 95.9% of the previous year’s corresponding period.」
Medical segment revenue exceeded the previous year’s corresponding period, while segment profit fell below it. The physician placement business is progressing broadly in line with plan. - FY2019-Q1RestatedAnnual report
「As a result, the medical segment recorded revenue of ¥1,182 million, up 103.3% year on year, and segment profit (operating profit) of ¥364 million, down to 96.1% of the previous year’s corresponding period.」
Medical segment revenue exceeded the previous year’s corresponding period, while segment profit fell below it. The physician placement business is described as having progressed broadly in line with plan. - FY2018RestatedAnnual report
「As a result, the medical segment recorded revenue of ¥3,557 million, up 107.5% from the previous fiscal year, and segment profit (operating profit) of ¥575 million, up 132.8%.」
Confirms that full-year medical segment revenue and segment profit exceeded the previous year, driven by the physician placement business. - FY2018-Q3RestatedAnnual report
「As a result, the medical segment recorded revenue of ¥2,929 million, up 106.1% year on year, and segment profit (operating profit) of ¥581 million, up 120.2%.」
Medical segment revenue and segment profit exceeded the previous year’s corresponding period, driven by the physician placement business. - FY2018-Q1RestatedAnnual report
「As a result, the medical segment recorded revenue of ¥1,144 million, up 106.0% year on year, and segment profit (operating profit) of ¥379 million, up 137.4%.」
Continues to show that quarterly medical segment revenue and segment profit exceeded the previous year’s corresponding period, driven by the physician placement business. - FY2017RestatedAnnual report
「As a result, the medical segment recorded revenue of ¥3,310 million, up 113.8% from the previous fiscal year, and segment profit (operating profit) of ¥433 million, up 105.9%.」
Full-year medical segment revenue and segment profit exceeded the previous year, driven by the physician placement business. - FY2017-Q3RestatedAnnual report
「Supported by strong performance in the physician placement business, revenue and segment profit for the cumulative third quarter of the consolidated fiscal year progressed steadily. As a result, the medical segment recorded revenue of ¥2,760 million, up 114.5% year on year, and segment profit (operating profit) of ¥483 million, up 114.6%.」
Medical segment revenue and segment profit exceeded the previous year’s corresponding period, driven by the physician placement business. - FY2017-Q2RestatedAnnual report
「Supported by strong performance in the physician placement business, revenue and segment profit for the cumulative second quarter of the consolidated fiscal year progressed steadily. As a result, the medical segment recorded revenue of ¥2,168 million, up 116.0% year on year, and segment profit (operating profit) of ¥549 million, up 117.3%.」
Continues to show year-on-year increases in medical segment revenue and profit driven by the physician placement business. - FY2017-Q1First statedAnnual report
「Supported by strong performance in the physician placement business, revenue and segment profit for the cumulative first quarter of the consolidated fiscal year progressed steadily. As a result, the medical segment recorded revenue of ¥1,079 million, up 120.6% year on year, and segment profit (operating profit) of ¥276 million, up 117.4%.」
Shows numerically the increase in medical segment revenue and profit driven by the physician placement business.